Carna Biosciences, Inc. (TYO:4572)

Japan flag Japan · Delayed Price · Currency is JPY
222.00
+1.00 (0.45%)
Aug 29, 2025, 11:29 AM JST
0.45%
Market Cap4.22B
Revenue (ttm)572.00M
Net Income (ttm)-2.14B
Shares Out19.10M
EPS (ttm)-113.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume49,300
Average Volume409,450
Open222.00
Previous Close221.00
Day's Range221.00 - 224.00
52-Week Range216.00 - 466.00
Beta0.54
RSI30.35
Earnings DateAug 6, 2025

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable smal... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 63
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4572
Full Company Profile

Financial Performance

In 2024, Carna Biosciences's revenue was 636.00 million, a decrease of -60.86% compared to the previous year's 1.63 billion. Losses were -2.18 billion, 89.1% more than in 2023.

Financial Statements

News

There is no news available yet.